Inarigivir (ammonium)

Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses[1][2].

Product Specifications

CAS Number

[2172788-92-8]

Product Name Alternative

ORI-9020 (ammonium) ; SB-9000 (ammonium)

UNSPSC

12352005

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/inarigivir-ammonium.html

Concentration

10mM

Purity

99.04

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

NC1=C(N=CN2[C@@H]3O[C@H](COP(O[C@H]4[C@@H](OC)[C@H](N5C=CC(NC5=O)=O)O[C@@H]4CO)(S)=O)[C@@H](O)C3)C2=NC=N1.N

Molecular Formula

C20H29N8O10PS

Molecular Weight

604.53

References & Citations

[1]Iyer RP, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother. 2004 Jun;48 (6) :2318-20.|[2]Danni Colledge, et al. The Novel Antiviral Agent Inarigivir Inhibits Both Nucleos (t) ide Analogue and Capsid Assembly Inhibitor Resistant HBV in vitro.